Healthcare >> CEO Interviews >> March 24, 2003

Charles Casamento – Questcor Pharmaceuticals Inc (qsc)

CHARLES J. CASAMENTO is Chairman, President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. He joined RiboGene, Inc., in June 1993. On November 17, 1999, RiboGene and Cypros merged to form Questcor Pharmaceuticals, Inc. The company currently has five products on the market in the US. In the fourth quarter of 2003, driven by the introduction of a new product, Nascobal, Questcor revenues hit a record level and the company recorded its first profitable quarter with net income of $324,000. Mr. Casamento closed 37 partnership, product acquisition, R&D collaborations and merger transactions with Questcor. Previously, Mr. Casamento was President and Chief Executive Officer of Interneuron Pharmaceuticals, Inc., which he co-founded in February 1989. From 1986 to 1989, he was Senior Vice President at Genzyme Corporation. From 1983 to 1986, he was Vice President, Business Development and Planning at the Critical Care Division of American Hospital Supply Corporation, and from 1970 to 1983 he held managerial positions with Johnson & Johnson, Hoffmann-LaRoche and Sandoz. Mr. Casamento received an MBA in 1971 from Iona College, New Rochelle, New York and a BS in Pharmacy in 1968 from Fordham University College of Pharmacy in New York City. He is a member of the Board of Directors of Cortex Pharmaceuticals, Inc., in Irvine, California; SuperGen Inc. in Dublin, California; and the Catholic Medical Mission Board, a non-profit organization, in New York, New York which serves the medical needs of people in Third World countries. He is a licensed pharmacist in the states of New York and New Jersey. Profile
TWST: Would you give us the background of Questcor


Mr. Casamento: Questcor is a company that is marketing

pharmaceutical products in hospitals in critical-care and acute-